Breaking News Instant updates and real-time market news.

TSHA

Taysha Gene Therapies

$21.35 /

+1.49 (+7.50%)

07:05
04/12/21
04/12
07:05
04/12/21
07:05

Taysha Gene Therapies acquires exclusive rights to AAV9 gene therapy program

Taysha Gene Therapies announced the acquisition of exclusive worldwide rights to a clinical-stage AAV9 gene therapy program, now known as TSHA-120, for the treatment of giant axonal neuropathy, or GAN. TSHA-120 is an intrathecally dosed AAV9 gene therapy currently being evaluated in a clinical trial for the treatment of GAN. The trial is being conducted by the National Institutes of Health, or NIH, in close collaboration with a patient advocacy group focused on finding treatments and cures for GAN. TSHA-120 has received rare pediatric disease and orphan drug designations from the FDA for the treatment of GAN. The National Institute of Neurological Disorders and Stroke, or NINDS, division of the NIH is conducting the ongoing open-label, non-randomized, dose-escalation clinical trial of TSHA-120 for the treatment of GAN. The primary endpoint is safety, with secondary endpoints measuring efficacy using pathologic, physiologic, functional, and clinical markers. A primary measure of clinical efficacy is the Motor Function Measure 32 score, a quantitative scale designed to assess the severity and progression of motor function abilities. There is precedent for its use in multiple clinical studies for neuromuscular diseases, including spinal muscular atrophy amongst others. To date, 14 patients have been dosed with one of four dose levels of TSHA-120. TSHA-120 has demonstrated a dose-response relationship with arrest of disease progression at the second-highest dose level (1.8x1014 total vector genomes at one-year post-treatment, affecting a statistically significant eight-point improvement on the MFM32 score. A 4-point change on the MFM32 score is considered clinically meaningful. Six of these patients treated at therapeutic dose levels have shown sustained dose-dependent improvements in MFM32 scores for more than three years. Long-term results demonstrated that treatment with TSHA-120 at multiple dose levels was well-tolerated with no severe drug-related adverse events. Additional data are expected later this year, including results from the highest dose cohort. Before the end of the year, Taysha intends to request an End-of-Phase meeting with the FDA and engage with the European Medicines Agency, or EMA, and the Pharmaceuticals and Medical Devices Agency, or PMDA)in Japan to discuss the regulatory pathway for TSHA-120. Taysha expects to provide a regulatory and clinical update on TSHA-120, including data from the 3.5x1014 total vg cohort by year-end. Under the terms of the agreement, in exchange for granting Taysha the exclusive worldwide rights to TSHA-120, the GAN patient advocacy group will receive an upfront payment of $5.5M and will be eligible to receive clinical, regulatory and commercial milestones totaling up to $19.3M, as well as a low, single-digit royalty on net sales upon commercialization of the product.

  • 12

    Apr

  • 24

    Sep

TSHA Taysha Gene Therapies
$21.35 /

+1.49 (+7.50%)

03/04/21 Chardan
Taysha Gene Therapies price target raised to $60 from $45 at Chardan
02/23/21 William Blair
William Blair starts Taysha with Outperform, $46 fair-value estimate
02/23/21 William Blair
William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
02/23/21 William Blair
Taysha Gene Therapies initiated with an Outperform at William Blair

TODAY'S FREE FLY STORIES

Options
Invitae put volume heavy and directionally bearish » 10:55
06/22/21
06/22
10:55
06/22/21
10:55
NVTA

Invitae

$33.28 /

-0.11 (-0.33%)

Bearish flow noted in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NVTA Invitae
$33.28 /

-0.11 (-0.33%)

NVTA Invitae
$33.28 /

-0.11 (-0.33%)

06/21/21 Wells Fargo
Invitae price target raised to $35 from $30 at Wells Fargo
06/15/21 Raymond James
Invitae initiated with an Outperform at Raymond James
06/15/21 Raymond James
Invitae initiated with an Outperform at Raymond James
06/03/21 Goldman Sachs
Invitae initiated with a Neutral at Goldman Sachs
NVTA Invitae
$33.28 /

-0.11 (-0.33%)

  • 22
    Jan
NVTA Invitae
$33.28 /

-0.11 (-0.33%)

NVTA Invitae
$33.28 /

-0.11 (-0.33%)

Conference/Events
Colony Capital to hold virtual investor day » 10:55
06/22/21
06/22
10:55
06/22/21
10:55
CLNY

Colony Capital

/

+

Virtual Investor Day to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CLNY Colony Capital
/

+

CLNY Colony Capital
/

+

06/21/21
Fly Intel: Top five analyst initiations
06/21/21 Wells Fargo
Colony Capital initiated with an Overweight at Wells Fargo
06/04/21 B. Riley
Colony Capital resumed with a Buy at B. Riley
05/21/21 Wells Fargo
Landmark Infrastructure upgraded to Equal Weight from Underweight at Wells Fargo
CLNY Colony Capital
/

+

CLNY Colony Capital
/

+

CLNY Colony Capital
/

+

CLNY Colony Capital
/

+

Conference/Events
Federal Reserve Bank of San Francisco participates in a virtual discussion » 10:55
06/22/21
06/22
10:55
06/22/21
10:55

Federal Reserve Bank of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Nutanix to hold virtual investor day » 10:55
06/22/21
06/22
10:55
06/22/21
10:55
NTNX

Nutanix

$36.58 /

+0.24 (+0.66%)

Virtual Investor Day to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NTNX Nutanix
$36.58 /

+0.24 (+0.66%)

NTNX Nutanix
$36.58 /

+0.24 (+0.66%)

05/27/21 Piper Sandler
Nutanix price target raised to $38 from $37 at Piper Sandler
05/04/21 JPMorgan
JPMorgan upgrades Nutanix to Overweight into 'period of relative stability'
05/04/21 JPMorgan
Nutanix upgraded to Overweight from Neutral at JPMorgan
04/29/21 Piper Sandler
Piper Sandler upgrades Nutanix with transition 'beginning to inflect'
NTNX Nutanix
$36.58 /

+0.24 (+0.66%)

NTNX Nutanix
$36.58 /

+0.24 (+0.66%)

NTNX Nutanix
$36.58 /

+0.24 (+0.66%)

Periodicals
Foxconn offers record bonuses to recruit workers for iPhone 13, SCMP reports » 10:54
06/22/21
06/22
10:54
06/22/21
10:54
HNHPF

Hon Hai Precision

$7.84 /

-0.08 (-1.01%)

, AAPL

Apple

$132.30 /

+0.01 (+0.01%)

Foxconn Technology Group…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HNHPF Hon Hai Precision
$7.84 /

-0.08 (-1.01%)

AAPL Apple
$132.30 /

+0.01 (+0.01%)

HNHPF Hon Hai Precision
$7.84 /

-0.08 (-1.01%)

AAPL Apple
$132.30 /

+0.01 (+0.01%)

06/21/21 Wedbush
Apple likely to launch iPhone 13 in third week of September, says Wedbush
06/17/21 Loop Capital
Loop Capital starts Cirrus Logic at Buy, cites content gains at Apple
06/11/21 Argus
Apple underperformance due to sector rotation, not misfires, says Argus
06/08/21 RBC Capital
Fisker initiated with an Outperform at RBC Capital
AAPL Apple
$132.30 /

+0.01 (+0.01%)

HNHPF Hon Hai Precision
$7.84 /

-0.08 (-1.01%)

AAPL Apple
$132.30 /

+0.01 (+0.01%)

HNHPF Hon Hai Precision
$7.84 /

-0.08 (-1.01%)

AAPL Apple
$132.30 /

+0.01 (+0.01%)

AAPL Apple
$132.30 /

+0.01 (+0.01%)

Recommendations
WWE too small to 'go it alone' in today's streaming world, says Needham » 10:54
06/22/21
06/22
10:54
06/22/21
10:54
WWE

WWE

$57.22 /

-0.56 (-0.97%)

, CMCSA

Comcast

$57.38 /

+0.09 (+0.16%)

Needham analyst Laura…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WWE WWE
$57.22 /

-0.56 (-0.97%)

CMCSA Comcast
$57.38 /

+0.09 (+0.16%)

WWE WWE
$57.22 /

-0.56 (-0.97%)

04/23/21 Morgan Stanley
WWE price target raised to $65 from $60 at Morgan Stanley
04/08/21 MKM Partners
WWE financials becoming more predictable, says MKM Partners
02/05/21 Needham
WWE price target raised to $65 from $50 at Needham
01/27/21 MKM Partners
WWE price target raised to $65 from $60 at MKM Partners
CMCSA Comcast
$57.38 /

+0.09 (+0.16%)

06/17/21 TD Securities
TD upgrades Altice USA to Buy ahead of second half growth pickup
05/24/21 HSBC
Comcast price target raised to $64 from $56 at HSBC
05/18/21 Benchmark
Comcast selloff on Discovery-WarnerMedia news 'excessive,' says Benchmark
05/17/21 Citi
Discovery upgraded to Buy from Neutral at Citi
WWE WWE
$57.22 /

-0.56 (-0.97%)

CMCSA Comcast
$57.38 /

+0.09 (+0.16%)

CMCSA Comcast
$57.38 /

+0.09 (+0.16%)

WWE WWE
$57.22 /

-0.56 (-0.97%)

CMCSA Comcast
$57.38 /

+0.09 (+0.16%)

CMCSA Comcast
$57.38 /

+0.09 (+0.16%)

Hot Stocks
Westwater Resources trading halted, news pending  10:50
06/22/21
06/22
10:50
06/22/21
10:50
WWR

Westwater Resources

$4.49 /

+0.03 (+0.67%)

 
ShowHide Related Items >><<
WWR Westwater Resources
$4.49 /

+0.03 (+0.67%)

WWR Westwater Resources
$4.49 /

+0.03 (+0.67%)

General news
European Fixed Income Summary: » 10:50
06/22/21
06/22
10:50
06/22/21
10:50
$ECON

Economic Data

/

+

European Fixed Income…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

General news
U.S. existing home sales beat estimates » 10:50
06/22/21
06/22
10:50
06/22/21
10:50
$ECON

Economic Data

/

+

U.S. existing home sales…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

Options
Exxon Mobil call volume above normal and directionally bullish » 10:45
06/22/21
06/22
10:45
06/22/21
10:45
XOM

Exxon Mobil

$63.26 /

+0.68 (+1.09%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
XOM Exxon Mobil
$63.26 /

+0.68 (+1.09%)

XOM Exxon Mobil
$63.26 /

+0.68 (+1.09%)

06/16/21 Oppenheimer
MSCI price target raised to $543 from $533 at Oppenheimer
06/09/21 Goldman Sachs
Goldman Sachs keeps Buy on Hess, Exxon Mobil after successful Longtail appraisal
06/03/21 Barclays
Exxon Mobil price target raised to $70 from $65 at Barclays
05/17/21 Mizuho
Exxon Mobil price target raised to $66 from $58 at Mizuho
XOM Exxon Mobil
$63.26 /

+0.68 (+1.09%)

XOM Exxon Mobil
$63.26 /

+0.68 (+1.09%)

XOM Exxon Mobil
$63.26 /

+0.68 (+1.09%)

XOM Exxon Mobil
$63.26 /

+0.68 (+1.09%)

Conference/Events
Cisco participates in a conference call with Goldman Sachs » 10:45
06/22/21
06/22
10:45
06/22/21
10:45
CSCO

Cisco

$53.11 /

-0.08 (-0.15%)

Management discusses the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CSCO Cisco
$53.11 /

-0.08 (-0.15%)

CSCO Cisco
$53.11 /

-0.08 (-0.15%)

05/21/21
Fly Intel: Top five analyst downgrades
05/21/21 DZ Bank
Cisco downgraded to Hold from Buy at DZ Bank
05/20/21 Morgan Stanley
Cisco tone on growth runway leaves Morgan Stanley confident
05/20/21 Oppenheimer
Cisco price target raised to $55 from $50 at Oppenheimer
CSCO Cisco
$53.11 /

-0.08 (-0.15%)

CSCO Cisco
$53.11 /

-0.08 (-0.15%)

CSCO Cisco
$53.11 /

-0.08 (-0.15%)

CSCO Cisco
$53.11 /

-0.08 (-0.15%)

Conference/Events
Vir Biotechnology to host conference call » 10:45
06/22/21
06/22
10:45
06/22/21
10:45
VIR

Vir Biotechnology

$49.64 /

+0.54 (+1.10%)

Management discusses the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VIR Vir Biotechnology
$49.64 /

+0.54 (+1.10%)

VIR Vir Biotechnology
$49.64 /

+0.54 (+1.10%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
  • 08
    Jul
VIR Vir Biotechnology
$49.64 /

+0.54 (+1.10%)

Hot Stocks
Pinterest, Snap shares sold by ARK Fintech Innovation ETF » 10:44
06/22/21
06/22
10:44
06/22/21
10:44
PINS

Pinterest

$73.33 /

+2.18 (+3.06%)

, SNAP

Snap

$62.94 /

-0.66 (-1.04%)

, ARKF

ARK Fintech Innovation ETF

$51.75 /

+0.02 (+0.04%)

, ARKQ

ARK Autonomous Technology & Robotics ETF

$82.24 /

+0.37 (+0.45%)

, BABA

Alibaba

$210.09 /

-0.95 (-0.45%)

, BLDE

Blade Air Mobility

$10.65 /

-0.6 (-5.33%)

ARK Investment Management…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PINS Pinterest
$73.33 /

+2.18 (+3.06%)

SNAP Snap
$62.94 /

-0.66 (-1.04%)

ARKQ ARK Autonomous Technology & Robotics ETF
$82.24 /

+0.37 (+0.45%)

BABA Alibaba
$210.09 /

-0.95 (-0.45%)

BLDE Blade Air Mobility
$10.65 /

-0.6 (-5.33%)

PINS Pinterest
$73.33 /

+2.18 (+3.06%)

05/10/21 Arete
Pinterest initiated with a Buy at Arete
05/10/21 Citi
Pinterest price target lowered to $65 from $85 at Citi
04/30/21 MKM Partners
Twitter price target lowered to $83 from $95 at MKM Partners
04/28/21 Wedbush
Pinterest price target lowered to $91 from $100 at Wedbush
SNAP Snap
$62.94 /

-0.66 (-1.04%)

06/02/21 Cowen
Poshmark pent up demand for apparel should bode well, says Cowen
05/21/21 Piper Sandler
Snap remains top pick in social advertising at Piper Sandler
05/10/21 Citi
Snap price target lowered to $42 from $47 at Citi
05/04/21 Citi
Snap price target raised to $47 from $40 at Citi
ARKF ARK Fintech Innovation ETF
$51.75 /

+0.02 (+0.04%)

ARKQ ARK Autonomous Technology & Robotics ETF
$82.24 /

+0.37 (+0.45%)

BABA Alibaba
$210.09 /

-0.95 (-0.45%)

05/17/21 Susquehanna
Alibaba opportunity ahead despite regulatory concerns, says Susquehanna
05/14/21 Truist
Alibaba price target lowered to $290 from $315 at Truist
05/14/21 Benchmark
Alibaba price target lowered to $285 from $310 at Benchmark
05/14/21 Baird
Alibaba price target lowered to $270 from $285 at Baird
BLDE Blade Air Mobility
$10.65 /

-0.6 (-5.33%)

06/03/21
Fly Intel: Top five analyst initiations
06/03/21 Citi
Blade Air Mobility initiated with a Buy at Citi
PINS Pinterest
$73.33 /

+2.18 (+3.06%)

SNAP Snap
$62.94 /

-0.66 (-1.04%)

BABA Alibaba
$210.09 /

-0.95 (-0.45%)

PINS Pinterest
$73.33 /

+2.18 (+3.06%)

SNAP Snap
$62.94 /

-0.66 (-1.04%)

BABA Alibaba
$210.09 /

-0.95 (-0.45%)

BLDE Blade Air Mobility
$10.65 /

-0.6 (-5.33%)

PINS Pinterest
$73.33 /

+2.18 (+3.06%)

SNAP Snap
$62.94 /

-0.66 (-1.04%)

BABA Alibaba
$210.09 /

-0.95 (-0.45%)

PINS Pinterest
$73.33 /

+2.18 (+3.06%)

SNAP Snap
$62.94 /

-0.66 (-1.04%)

ARKF ARK Fintech Innovation ETF
$51.75 /

+0.02 (+0.04%)

BABA Alibaba
$210.09 /

-0.95 (-0.45%)

BLDE Blade Air Mobility
$10.65 /

-0.6 (-5.33%)

ARKF ARK Fintech Innovation ETF
$51.75 /

+0.02 (+0.04%)

Recommendations
Score Media rallies with Credit Suisse positive ahead of sports betting vote » 10:43
06/22/21
06/22
10:43
06/22/21
10:43
SCR

Score Media

$24.90 /

+2.54 (+11.36%)

Today, bill C-218 will be…

Today, bill C-218 will be voted on in the Senate, which would legalize single-game sports betting in Canada, Credit Suisse analyst Benjamin Chaiken tells investors in a research note. Only multi-game parlays are permitted in the country currently, and online gambling is limited to state-run lottery organizations. Chaiken says he's been following the bill closely and thinks there is a "high likelihood of passage." Score Media and Gaming is positioned to be a market leader, he contends in a research note titled "The King in the North." The positive momentum in the legislation has led to a rally in the shares but there remains "sufficient room for upside," writes Chaiken. He believes that Score Media is positioned to be a market leader in Canada and estimates around 20% of Canadian sports fans are Score users. At $22.50 per share, there is essentially zero value for the U.S. and zero value for any provinces outside of Ontario, Chaiken adds. He keeps an Outperform rating on Score Media with a $50 price target. The stock in early trading is up 10% to $30.44.

ShowHide Related Items >><<
SCR Score Media
$24.90 /

+2.54 (+11.36%)

03/23/21 Credit Suisse
Score Media initiated with an Outperform at Credit Suisse
03/22/21 Macquarie
Score Media initiated with an Outperform at Macquarie
  • 25
    Feb
SCR Score Media
$24.90 /

+2.54 (+11.36%)

SCR Score Media
$24.90 /

+2.54 (+11.36%)

SCR Score Media
$24.90 /

+2.54 (+11.36%)

Hot Stocks
Vivendi shareholders back spin-off of Universal Music Group » 10:40
06/22/21
06/22
10:40
06/22/21
10:40
VIVHY

Vivendi

$34.27 /

-0.12 (-0.35%)

, PSTH

Pershing Square Tontine Holdings

$22.94 /

+0.215 (+0.95%)

Vivendi (VIVHY) said…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VIVHY Vivendi
$34.27 /

-0.12 (-0.35%)

PSTH Pershing Square Tontine Holdings
$22.94 /

+0.215 (+0.95%)

VIVHY Vivendi
$34.27 /

-0.12 (-0.35%)

06/01/21
Fly Intel: Top five analyst downgrades
06/01/21 Bernstein
Vivendi downgraded to Market Perform from Outperform at Bernstein
05/14/21 Credit Suisse
Vivendi price target lowered to EUR 32.20 from EUR 32.40 at Credit Suisse
04/23/21 Barclays
Vivendi price target raised to EUR 32 from EUR 31 at Barclays
PSTH Pershing Square Tontine Holdings
$22.94 /

+0.215 (+0.95%)

  • 22
    Jul
VIVHY Vivendi
$34.27 /

-0.12 (-0.35%)

PSTH Pershing Square Tontine Holdings
$22.94 /

+0.215 (+0.95%)

VIVHY Vivendi
$34.27 /

-0.12 (-0.35%)

PSTH Pershing Square Tontine Holdings
$22.94 /

+0.215 (+0.95%)

PSTH Pershing Square Tontine Holdings
$22.94 /

+0.215 (+0.95%)

Hot Stocks
LexinFintech announces partnership with Huawei for Chinese consumer market » 10:39
06/22/21
06/22
10:39
06/22/21
10:39
LX

LexinFintech

$12.34 /

+0.215 (+1.77%)

LexinFintech announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LX LexinFintech
$12.34 /

+0.215 (+1.77%)

LX LexinFintech
$12.34 /

+0.215 (+1.77%)

06/14/21 Morgan Stanley
LexinFintech upgraded to Overweight from Equal Weight at Morgan Stanley
06/14/21 Morgan Stanley
LexinFintech upgraded to Overweight from Equal Weight at Morgan Stanley
05/05/21 CICC
LexinFintech initiated with an Outperform at CICC
03/31/21 Morgan Stanley
Morgan Stanley says 360 Finance, Lufax should be least impacted by new PBOC rule
Hot Stocks
J&J confirms EC grants marketing authorization for expanded Darzalex use » 10:37
06/22/21
06/22
10:37
06/22/21
10:37
JNJ

Johnson & Johnson

$163.89 /

+0.06 (+0.04%)

The Janssen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$163.89 /

+0.06 (+0.04%)

JNJ Johnson & Johnson
$163.89 /

+0.06 (+0.04%)

07:37 Today JPMorgan
Opioid settlement would be best case for manufacturers, says JPMorgan
06/08/21 Wedbush
Argenx price target lowered to $344 from $356 at Wedbush
06/08/21 Baird
Argenx price target lowered to $333 from $346 at Baird
06/07/21 BofA
BofA upgrades Biogen to Neutral with $400 price target after Aduhelm approved
JNJ Johnson & Johnson
$163.89 /

+0.06 (+0.04%)

JNJ Johnson & Johnson
$163.89 /

+0.06 (+0.04%)

JNJ Johnson & Johnson
$163.89 /

+0.06 (+0.04%)

JNJ Johnson & Johnson
$163.89 /

+0.06 (+0.04%)

Conference/Events
Myovant Sciences participates in a conference call with JPMorgan » 10:35
06/22/21
06/22
10:35
06/22/21
10:35
MYOV

Myovant Sciences

$21.17 /

-0.2 (-0.94%)

Conference call with CEO…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MYOV Myovant Sciences
$21.17 /

-0.2 (-0.94%)

MYOV Myovant Sciences
$21.17 /

-0.2 (-0.94%)

05/13/21 Citi
Myovant Sciences price target lowered to $24 from $30 at Citi
05/03/21 JPMorgan
Myovant Sciences price target lowered to $32 from $38 at JPMorgan
01/08/21 SVB Leerink
Myovant Sciences downgraded to Market Perform from Outperform at SVB Leerink
01/06/21 Goldman Sachs
Myovant Sciences downgraded to Neutral from Buy at Goldman Sachs
MYOV Myovant Sciences
$21.17 /

-0.2 (-0.94%)

MYOV Myovant Sciences
$21.17 /

-0.2 (-0.94%)

Options
Agenus put volume heavy and directionally bearish » 10:35
06/22/21
06/22
10:35
06/22/21
10:35
AGEN

Agenus

$5.34 /

+0.045 (+0.85%)

Bearish flow noted in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AGEN Agenus
$5.34 /

+0.045 (+0.85%)

AGEN Agenus
$5.34 /

+0.045 (+0.85%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
09/22/20 B. Riley FBR
B. Riley FBR calls Agenus 'hidden gem' amidst ESMO data releases
09/18/20 Jefferies
Agenus price target raised to $8 from $5 at Jefferies
AGEN Agenus
$5.34 /

+0.045 (+0.85%)

AGEN Agenus
$5.34 /

+0.045 (+0.85%)

AGEN Agenus
$5.34 /

+0.045 (+0.85%)

General news
Treasury Action: the markets are little changed » 10:35
06/22/21
06/22
10:35
06/22/21
10:35
$ECON

Economic Data

/

+

Treasury Action: the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

Hot Stocks
FDA considers delaying decision on Incyte's retifanlimab » 10:34
06/22/21
06/22
10:34
06/22/21
10:34
INCY

Incyte

$85.26 /

+0.31 (+0.36%)

The FDA is considering…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
INCY Incyte
$85.26 /

+0.31 (+0.36%)

INCY Incyte
$85.26 /

+0.31 (+0.36%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
INCY Incyte
$85.26 /

+0.31 (+0.36%)

INCY Incyte
$85.26 /

+0.31 (+0.36%)

INCY Incyte
$85.26 /

+0.31 (+0.36%)

INCY Incyte
$85.26 /

+0.31 (+0.36%)

Hot Stocks
Lincoln Financial appoints Jen Warne as EVP, CPO » 10:33
06/22/21
06/22
10:33
06/22/21
10:33
LNC

Lincoln National

$61.41 /

-0.39 (-0.63%)

Lincoln Financial Group…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LNC Lincoln National
$61.41 /

-0.39 (-0.63%)

LNC Lincoln National
$61.41 /

-0.39 (-0.63%)

05/18/21 B. Riley
Lincoln National price target raised to $72 from $56 at B. Riley
05/07/21 RBC Capital
Lincoln National price target raised to $69 from $59 at RBC Capital
04/20/21 UBS
Lincoln National initiated with a Neutral at UBS
04/12/21 Barclays
Lincoln National price target raised to $66 from $61 at Barclays
LNC Lincoln National
$61.41 /

-0.39 (-0.63%)

LNC Lincoln National
$61.41 /

-0.39 (-0.63%)

LNC Lincoln National
$61.41 /

-0.39 (-0.63%)

Hot Stocks
Blackstone hires Devin Glenn as Global Head of Diversity, Equity, Inclusion » 10:31
06/22/21
06/22
10:31
06/22/21
10:31
BX

Blackstone

$98.88 /

+0.56 (+0.57%)

Blackstone announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BX Blackstone
$98.88 /

+0.56 (+0.57%)

BX Blackstone
$98.88 /

+0.56 (+0.57%)

06/07/21 MoffettNathanson
QTS Realty buyout 'very appealing result,' says MoffettNathanson
04/27/21 Argus
Blackstone price target raised to $100 from $82 at Argus
04/23/21 Barclays
Blackstone price target raised to $95 from $85 at Barclays
04/23/21 Deutsche Bank
Blackstone price target raised to $76 from $66 at Deutsche Bank
BX Blackstone
$98.88 /

+0.56 (+0.57%)

BX Blackstone
$98.88 /

+0.56 (+0.57%)

BX Blackstone
$98.88 /

+0.56 (+0.57%)

BX Blackstone
$98.88 /

+0.56 (+0.57%)

Periodicals
Teva settles Mississippi generic pricing case for $925,0000, Bloomberg reports » 10:31
06/22/21
06/22
10:31
06/22/21
10:31
TEVA

Teva

$10.21 /

+0.1 (+0.99%)

Teva Pharmaceutical…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TEVA Teva
$10.21 /

+0.1 (+0.99%)

TEVA Teva
$10.21 /

+0.1 (+0.99%)

07:37 Today JPMorgan
Opioid settlement would be best case for manufacturers, says JPMorgan
05/04/21 UBS
Teva downgraded to Neutral from Buy at UBS
04/06/21 RBC Capital
Teva transferred with a Sector Perform at RBC Capital
01/26/21 Piper Sandler
Amarin in 'strong position' against Health Net, says Piper Sandler
TEVA Teva
$10.21 /

+0.1 (+0.99%)

TEVA Teva
$10.21 /

+0.1 (+0.99%)

TEVA Teva
$10.21 /

+0.1 (+0.99%)

TEVA Teva
$10.21 /

+0.1 (+0.99%)

Conference/Events
Wedbush Internet analyst to hold an analyst/industry conference call » 10:31
06/22/21
06/22
10:31
06/22/21
10:31
WIX

Wix.com

$292.78 /

+6.8 (+2.38%)

Internet Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
WIX Wix.com
$292.78 /

+6.8 (+2.38%)

WIX Wix.com
$292.78 /

+6.8 (+2.38%)

06/14/21 RBC Capital
Wix.com price target raised to $315 from $300 at RBC Capital
06/14/21 RBC Capital
Squarespace initiated with a Sector Perform at RBC Capital
06/14/21 Goldman Sachs
Squarespace initiated with a Buy at Goldman Sachs
06/08/21 Atlantic Equities
Wix.com initiated with an Overweight at Atlantic Equities
WIX Wix.com
$292.78 /

+6.8 (+2.38%)

WIX Wix.com
$292.78 /

+6.8 (+2.38%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.